# Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer
Canonical URL: https://biopharmsignal.com/news/RVMD/revolution-medicines-statement-on-fda-expanded-access-authorization-for-daraxonrasib-in-patients-with-previously-treated-metastatic-pancreatic-cancer
Ticker: RVMD
Company: Revolution Medicines
Source: Revolution Medicines
Published: 2026-05-01 14:41 EST
Original Source URL: https://ir.revmed.com
## Summary

The U.S. Food and Drug Administration (FDA) has issued a “safe to proceed” letter to Revolution Medicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib, an investigational RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic

## Article Body
The U.S. Food and Drug Administration (FDA) has issued a “safe to proceed” letter to Revolution Medicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib, an investigational RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic
## Recent Company News
- 2026-05-31 12:06 EST — [Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-asco-plenary-presentation-highlighting-unprecedented-results-from-pivotal-phase-3-rasolute-302-clinical-trial-of-daraxonrasib-in-previously-treated-metastatic-pancreatic-cancer) — Source: Revolution Medicines
- 2026-05-21 20:05 EST — [Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation](https://biopharmsignal.com/news/RVMD/revolution-medicines-to-host-investor-conference-call-on-positive-rasolute-302-results-following-2026-asco-presentation) — Source: Revolution Medicines
- 2026-05-06 22:00 EST — [Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-announces-publication-in-new-england-journal-of-medicine-of-phase-1-2-clinical-data-on-daraxonrasib-in-pancreatic-cancer) — Source: Revolution Medicines
- 2026-05-06 20:02 EST — [Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress](https://biopharmsignal.com/news/RVMD/revolution-medicines-reports-first-quarter-2026-financial-results-and-update-on-corporate-progress) — Source: Revolution Medicines
- 2026-05-01 14:41 EST — [Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer](https://biopharmsignal.com/news/RVMD/revolution-medicines-statement-on-fda-expanded-access-authorization-for-daraxonrasib-in-patients-with-previously-treated-metastatic-pancreatic-cancer) — Source: Revolution Medicines
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)